IDEAYA Biosciences
IDEAYA Biosciences' revenue rose 3024.4% to $219 million in fiscal 2025. Its operating margin was −72.8%, up from −4,671.1% a year earlier. Free cash flow was −$73 million. The diluted share count rose 8.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What IDEAYA Biosciences does
IDEAYA Biosciences is a precision medicine company that develops cancer drugs. It has no product approved for sale. Its work centers on drugs matched to the genetic drivers of a tumor, including a type called synthetic lethality, and on antibody-drug conjugates, which carry a cancer-killing drug to tumor cells.
Its most advanced drug, darovasertib, is an oral pill that blocks an enzyme called protein kinase C. It is tested for uveal melanoma, a rare eye cancer, in combination with crizotinib, a drug from Pfizer. The company is running trials in cancer that has spread and in earlier-stage disease where doctors might try to preserve the eye. Its pipeline has nine candidates in all.
IDEAYA has deals with Pfizer, Servier, Hengrui Pharma and Gilead for licensing or clinical studies. It has no product sales, and says it expects to keep losing money for the foreseeable future.
Its biggest risks, as it describes them
- It has no approved products, a short operating history and expects losses.
- It depends on third parties, including partners and companies that run its trials.
- Clinical trials may be delayed or fail, and early results may not carry over.
- Its drugs may not gain regulatory approval or sell well if they do.
- It may not be able to protect its patents.
Income statement
IDEAYA Biosciences lost money in fiscal 2025: a net loss of $114 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 247 | 365 | 525 | 676 | 639 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −708.0x | −1,041.7x | −1,948.2x | −13,079.0x | — |
| Current ratio | 5.6x | 11.7x | 19.6x | 15.0x | 11.3x |
| Quick ratio | 5.6x | 11.7x | 19.6x | 15.0x | 11.3x |
Cash flow
Projections
Project IDEAYA Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $1.6 million of IDEAYA Biosciences shares on the open market, and 1 insider sold $382,096, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Briseno Andres RuizChief Accounting Officer | Sold plan | 9,550 | $40.01 | $382,096 | Form 4 |
| Mar 2, 2026 | Jeffrey SteinDirector | Bought | 50,000 | $32.96 | $1.6 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −556.9% | −3,662.1% | 2,990.8% |
| Altman Z'' | 25.07 | 17.12 | 12.90 |
| Accruals ratio | 0.4% | −3.0% | −3.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put IDEAYA Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | |
| Puma Biotechnology | FY25 | −0.9% | 16.3% | 18.3% | 48.2% | −1.4x | 8 | Compare |
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | Compare |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
| Harrow | FY25 | 36.4% | 11.2% | 15.8% | — | 5.5x | 6 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 0 | 20 | 28 | 51 | 23 | 7 | 219 |
| Revenue growth | — | — | — | — | 43.0% | 82.3% | −54.1% | −70.1% | 3,024.4% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 12 | 32 | 34 | 40 | 58 | 90 | 130 | 295 | 315 |
| Operating income | −14 | −36 | −44 | −35 | −50 | −62 | −134 | −327 | −159 |
| Net income | −12 | −34 | −42 | −34 | −50 | −59 | −113 | −274 | −114 |
| Diluted EPS (US$) | −17.06 | −35.92 | −3.36 | −1.40 | −1.41 | −1.42 | −1.96 | −3.36 | −1.28 |
| Diluted shares (millions) | 1 | 1 | 12 | 25 | 35 | 41 | 58 | 82 | 88 |
| Cash flow | |||||||||
| Cash from operations | −12 | −28 | −39 | 56 | −56 | −87 | −115 | −248 | −71 |
| Capital expenditure | 2 | 2 | 1 | 0 | 3 | 3 | 2 | 4 | 2 |
| Free cash flow | −14 | −29 | −41 | 55 | −58 | −91 | −118 | −251 | −73 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 2 | 4 | 8 | 12 | 18 | 35 | 46 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 6 | 90 | 99 | 284 | 247 | 365 | 525 | 676 | 639 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — |
| Total assets | — | 96 | 113 | 298 | 381 | 388 | 649 | 1,124 | 1,109 |
| Total liabilities | — | 7 | 13 | 100 | 80 | 38 | 28 | 65 | 86 |
| Shareholders' equity | −16 | −49 | 100 | 198 | 302 | 350 | 621 | 1,059 | 1,023 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | −180.9% | −179.9% | −122.7% | −574.9% | −4,671.1% | −72.8% |
| Net margin | — | — | — | −176.6% | −178.1% | −115.2% | −483.1% | −3,921.1% | −52.0% |
| Free cash flow margin | — | — | — | 281.4% | −209.1% | −177.9% | −502.9% | −3,592.0% | −33.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | −166.1% | −95.6% | −556.9% | −3,662.1% | 2,990.8% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −163.2% | −23.1% | −19.9% | −18.0% | −23.3% | −32.7% | −10.9% |
| Return on assets | — | — | −40.1% | −16.8% | −14.6% | −15.2% | −21.8% | −30.9% | −10.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |